首页> 美国卫生研究院文献>OncoTargets and therapy >Pathological complete response induced by neoadjuvant treatment using BRAF and MEK inhibitors in a patient with unresectable BRAF V600E-mutant malignant melanoma of the gallbladder
【2h】

Pathological complete response induced by neoadjuvant treatment using BRAF and MEK inhibitors in a patient with unresectable BRAF V600E-mutant malignant melanoma of the gallbladder

机译:不可切除的BRAF V600E突变型胆囊恶性黑色素瘤患者使用BRAF和MEK抑制剂新辅助治疗诱导的病理完全反应

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Historically, patients with locally advanced or metastatic melanoma have an extremely poor prognosis. In recent years, major breakthroughs in cutaneous melanoma treatment have led to remarkable improvements in patient outcomes. However, there are limited published data on the efficacy of these novel therapies in the treatment of mucosal melanoma due to rarity of the disease. We report a case of successful neoadjuvant targeted therapy with BRAF and MEK inhibitors followed by radical surgical excision in a patient with advanced malignant melanoma of the gallbladder.
机译:从历史上看,患有局部晚期或转移性黑色素瘤的患者预后极差。近年来,皮肤黑素瘤治疗的重大突破已导致患者预后明显改善。然而,由于这种疾病的罕见性,关于这些新疗法在治疗粘膜黑素瘤中的功效的公开数据有限。我们报告了一个成功的BRAF和MEK抑制剂新辅助靶向治疗的案例,然后对晚期胆囊恶性黑色素瘤患者进行了根治性手术切除。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号